Search our site 
Advanced Search

Home | Contact us | About us |


You are in Home >> Papers >> Oncology

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

Created: 23/4/2007


Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED
J Urol. 2004 Mar;171(3):1071-6.

Southwest Oncology Group and European Organization for the Research and Treatment of Cancer Genitourinary Group, Loyola University Medical Center, Maywood, Illinois, USA.


  • Metastatic renal cancer is associated with a poor prognosis
  • Recent advances in immunotherapy for this problem have rekindled interest in cytoreductive nephrectomy
  • The current paper reports a combined analysis of 2 prospective randomized trials that used an identical study protocol

Materials and Methods

  • 331 patients were randomized to 2 identical protocols comparing cytoreductive nephrectomy plus interferon alpha-2b vs interferon alpha-2b alone in patients with metastatic renal cancer, in whom the primary tumor was present and believed to be respectable
  • Primary end point for each trial was overall survival with a secondary end point of the response rate
  • Patients were stratified at pre-randomization by performance status (0 or 1), site of metastases (lung only vs other) and disease measurability
  • All results were analyzed by intent to treat criteria


  • The combined analysis of these 2 trials yielded a median survival of 13.6 months for nephrectomy plus interferon vs 7.8 months for interferon alone
  • This difference represents a 31% decrease in the risk of death (p = 0.002)
  • There was no evidence of a difference in the size of the treatment effect according to pre-randomization stratification factors


  • Cytoreductive nephrectomy appears to improve significantly overall survival in patients with metastatic renal cancer treated with interferon immunotherapy independent of patient performance status, the site of metastases and the presence of measurable disease
  • Although it is highly statistically significant, the overall survival advantage is only 5.8 months for the entire group
  • These data emphasize the need to determine if this survival advantage can be further improved using more aggressive immunotherapy or other novel agents in the setting of cytoreductive nephrectomy

SiteSection: Article

Login Status  

You are not currently logged in.
UK/Ireland Registration
Overseas Registration

  Forgot your password?

All rights reserved © 2008.

UrologyUK has been developed by AnaesthesiaUK.